VITAMIN D TREATMENT OF PROSTATE CANCER

大量的实验和流行病学数据表明，1，25-二氢维生素D3(骨化三醇)对人前列腺癌细胞具有明显的抗增殖作用。我们进行了一项开放标签的非随机试点试验，以确定骨化三醇治疗早期复发前列腺癌是否安全有效。我们的假设是，与治疗前相比，骨化三醇治疗减缓了前列腺特异性抗原(PSA)的上升速度。在最初的放射治疗或手术治疗后，至少3次记录的血清PSA水平升高表明复发。7名受试者完成了6至15个月的骨化三醇治疗，从0.5ug开始。骨化三醇每日缓慢增加，最大剂量为2.5微克。每天根据个人的钙尿症和钙血症反应。每个受试者作为自己的对照，比较骨化三醇治疗前后PSA升高的速度。

Substantial experimental and epidemiological data indicate that 1,25-dihdroxyvitamin D3 (calcitriol) has potent antiproliferative effects on human prostate cancer cells. We performed an open label, nonrandomized pilot trial to determine whether calcitriol therapy is safe and efficacious for early recurrent prostate cancer. Our hypothesis was that calcitriol therapy slows the rate of rise of prostate specific antigen(PSA) compared with the pretreatment rate. After primary treatment with radiation or surgery recurrence was indicated by rising serum PSA levels documented on at least 3 occasions. Seven subjects completed 6 to 15 months of calcitriol therapy, starting with 0.5 ug. calcitriol daily and slowly increasing to a maximum dose of 2.5 ug. daily depending on individual calciuric and calcemic responses. Each subject served as his own control, comparing the rate of PSA rise before or after calcitriol treatment.